News & Updates
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.
Hyfe’s AI-powered cough monitoring is now available on Actigraph’s FDA-cleared LEAP wearable, enabling continuous, privacy-preserving cough tracking alongside key health biomarkers
Clinical Trial Results Demonstrate Alkaline Magnesium-Based Salt Aerosol Reduced Cough Frequency by up to 35% in Refractory Chronic Cough Patients with Cough Counts Measured Continuously by AI-Powered tech
Hyfe's cough tracker was used in study by University of Navarra, revealing significant variability in cough patterns. This breakthrough highlights potential for continuous, objective chronic cough monitoring.
CoughPro app introduces the world’s first digital Cough Management feature, offering AI-driven solutions for millions suffering from chronic cough.
Research demonstrates the accuracy of Hyfe’s automated cough monitoring process and is the first to observe differences in type and length of cough between men and women.
AI company transitions app to subscription model and adds exclusive new features for users in the UK, Canada, Europe and global users outside the U.S.
Hyfe's technology integrated into ActiGraph’s new FDA-cleared LEAP wearable device that will advance the use of remote patient monitoring in chronic cough clinical research.
Studies show remote patient monitoring technology better predicts cough exacerbations to ultimately improve quality of life and reduce healthcare costs for patients with chronic cough.
Hyfe is expanding into chronic cough treatment with the world's first digital therapeutic for cough, using a proprietary model that combines real time cough frequency with cough suppression therapy.
150 winners selected out of 13,000 private companies; Hyfe recognized for contributions in screening, monitoring and diagnostics technologies
Hyfe has entered into an agreement with Merck, to integrate its artificial intelligence-powered (AI) cough tracker technology into Merck’s consumer disease educational efforts.
Leader in acoustic epidemiology empowers health care providers, researchers, pharmaceutical companies, and patients with cough detection and classification platform
Scientists use Hyfe to confirm that continuous cough monitoring for Long COVID was more sensitive in evaluating cough variability and response to treatment compared to patient reported outcomes.
Dr. Peter Small, Hyfe Chief Medical Officer has delivered deliver an intervention to the G20 Meeting in Yogyakarta, Indonesia, on the role of digital innovation in addressing public health crises.
With apps and artificial intelligence, researchers want to use the cough to better diagnose asthma, Covid-19 and other respiratory illnesses
Accomplished physician, scientist, and product developer to lead Hyfe's efforts as it seeks to transform patient care through cough monitoring and diagnosis.
SEATTLE, March 30, 2022 - Dr. Peter Small, the Chief Medical Officer for Hyfe, Inc., an artificial intelligence company with a tool to detect and track cough using smartphone applications, was invited to deliver an intervention to the G20 Meeting in Yogyakarta, Indonesia, on March 29 and 30 2022, as part of a side meeting focused on the role of innovation in public health.
Speaking from his +35 years professional experience at the forefront of the fight against the TB epidemic, Dr. Small urged the G20 countries to embrace digital innovation in the fight against TB with the same determination that they have responded to the Covid19 pandemic.
There is a clear path out of today’s TB crisis”, said Dr. Small, “integrate and scale what TB showed to be possible in 2019 using the digital mindset of the COVID response. By embracing digital technology, TB care and control would hitch its wagon to the exponential engine of global innovation. To bend the epidemic curve downward, we need to bend the digital innovation curve upward.
Dr. Small, who has left the public sector to join Hyfe in 2021, has urged the G20 countries to bring the sense of urgency and the focus on data and digital technology that they demonstrated during the Covid response to other global health threats. Failing to do so will perpetuate the chaotic and inefficient propagation of unimpactful technology and ultimately cost billions of dollars and millions of avertable deaths. With leadership and strategic funding from the G20, we can pivot tuberculosis from crisis to exponential progress.
In many countries the Covid19 response has accelerated progress on their diigital health agenda, however, more efforts are needed to strengthen syndromic surveillance and to embrace novel digital innovation methods in screening, remote patient monitoring and patient self-care.
:Hyfe is the global market leader in cough frequency detection (“Fitbit for cough”) and is developing classification capabilities that allows its deployment in screening and diagnostics (“Shazam for cough”). Hyfe’s models are trained on the world’s largest and most diverse dataset of cough and cough-like sounds, containing more than 250M cough-like sound samples, all of them collected from the real world, across all continents and socio-demographic segments.
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.